Development of a novel pralidoxime chloride auto-injector device
Active Definitive Contract Awarded Last action
- Contract number
- 75A50124C00010
- Awardee
-
Kaleo, Inc. UEI LBM4GLJNDK31
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $33,258,615
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Solicitation · BAA23100SOL00004 · Posted Sep 26, 2023
- Contract value 99% obligated
-
- $33,258,615.00 Current, with exercised options
- $33,762,976.00 Potential, with all options
- Completion date 56% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Richmond, VA 23219, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $3,784,396 | |
| Exercise an Option | $25,996,477 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $3,477,742 |
About this award
The Office of the Assistant Secretary for Preparedness and Response (civilian agency within the Department of Health and Human Services) awarded a $33.76 million cost-plus-fixed-fee definitive contract to Kaleo, Inc. for development of a novel pralidoxime chloride auto-injector device, with award date April 11, 2024 and ultimate completion date October 31, 2028. No set-aside was used.
The originating solicitation was a BARDA (Biomedical Advanced Research and Development Authority) multi-stage research and development initiative seeking medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The pralidoxime chloride auto-injector falls under the chemical medical countermeasures area of interest. Proposals were evaluated on program relevance, scientific and technical merit, offeror capabilities and experience, cost realism, and past performance.
Place of performance is Richmond, VA 23219. The solicitation contemplated multiple awards of various values and contract types across twelve areas of interest, with work to be performed in the United States.
Quick answers
Who was awarded contract 75A50124C00010?
75A50124C00010 was awarded to Kaleo, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on April 11, 2024.
How much is contract 75A50124C00010 worth?
The government has obligated $33,258,615 on 75A50124C00010. Its potential value, with all options, is $33,762,976.
Was contract 75A50124C00010 competed?
The extent of competition for 75A50124C00010 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award